Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,445 USD | +3,21% | -14,11% | -59,77% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 3,22 mln. 3,53 mln. 3,3 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | 10 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,11% |
Recentste transcriptie over Altamira Therapeutics Ltd.
1 dag | +2,86% | ||
1 week | -14,11% | ||
Lopende maand | -32,37% | ||
1 maand | -19,08% | ||
3 maanden | -33,33% | ||
6 maanden | -58,08% | ||
Lopend jaar | -59,77% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Meyer
CEO | Chief Executive Officer | 56 | 01-04-03 |
Marcel Gremaud
DFI | Director of Finance/CFO | 66 | 01-11-21 |
Covadonga Pañeda
COO | Chief Operating Officer | 51 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Alain Munoz
BRD | Director/Board Member | 75 | 01-03-18 |
Mats Blom
BRD | Director/Board Member | 59 | 01-04-17 |
Thomas Meyer
CEO | Chief Executive Officer | 56 | 01-04-03 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
22-04-24 | 1,4 | -0,99% | 107 242 |
23-04-24 | 1,58 | +12,86% | 110 808 |
22-04-24 | 1,4 | -0,99% | 107 242 |
19-04-24 | 1,414 | -5,73% | 46 743 |
18-04-24 | 1,5 | +1,35% | 24 812 |
slotkoers Nasdaq, 22 april 2024
Meer koersenKwartaalomzet - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-59,77% | 3,54 mln. | |
-1,67% | 105 mld. | |
+3,61% | 97,5 mld. | |
+1,86% | 22,19 mld. | |
-16,44% | 21,33 mld. | |
-8,49% | 18,68 mld. | |
-42,33% | 16,6 mld. | |
-20,55% | 14,52 mld. | |
+5,24% | 14,09 mld. | |
+26,23% | 10,99 mld. |